专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL261599A Hepatitis b antiviral agents 未知
公开(公告)号：IL261599A
公开(公告)日：2022-03-01
申请号：IL26159918
申请日：2018-09-04
申请人： ENANTA PHARM INC , QIU YAO LING , GAO XURI , LI WEI , CAO HUI , JIN MEIZHONG , KASS JORDEN , PENG XIAOWEN , OR YAT SUN
发明人： QIU YAO-LING , GAO XURI , LI WEI , CAO HUI , JIN MEIZHONG , KASS JORDEN , PENG XIAOWEN , OR YAT SUN
IPC分类号： A61K31/18 , A61K31/167 , A61K31/196 , A61K31/215 , A61K31/223 , A61K31/277 , A61K31/325 , A61K31/335 , A61K31/336 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/39 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/421 , A61K31/426 , A61K31/439 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4425 , A61K31/445 , A61K31/4545 , A61K31/5377 , A61K31/655 , C07B59/00
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

2. 发明专利

IL263535D0 Hepatitis b antiviral agents 未知
公开(公告)号：IL263535D0
公开(公告)日：2019-01-31
申请号：IL26353518
申请日：2018-12-06
申请人： ENANTA PHARM INC , QIU YAO LING , CAO HUI , PENG XIAOWEN , LI WEI , KASS JORDEN , GAO XURI , JIN MEIZHONG , OR YAT SUN
发明人： QIU YAO-LING , CAO HUI , PENG XIAOWEN , LI WEI , KASS JORDEN , GAO XURI , JIN MEIZHONG , OR YAT SUN
IPC分类号： C07D20060101

3. 发明专利

IL261599D0 Hepatitis b antiviral agents 未知
公开(公告)号：IL261599D0
公开(公告)日：2018-10-31
申请号：IL26159918
申请日：2018-09-04
申请人： ENANTA PHARM INC , QIU YAO LING , GAO XURI , LI WEI , CAO HUI , JIN MEIZHONG , KASS JORDEN , PENG XIAOWEN , OR YAT SUN
发明人： QIU YAO-LING , GAO XURI , LI WEI , CAO HUI , JIN MEIZHONG , KASS JORDEN , PENG XIAOWEN , OR YAT SUN
IPC分类号： C07D20060101
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

4. 发明申请

WO2012158861A2 PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES 审中-公开
标题翻译：制备5-亚苄基[2.4]庚-6-烯羧酸及其衍生物的方法
公开(公告)号：WO2012158861A2
公开(公告)日：2012-11-22
申请号：PCT/US2012038240
申请日：2012-05-17
申请人： ENANTA PHARM INC , QIU YAO-LING , PENG XIAOWEN , KIM IN JONG , CAO HUI , TANG DATONG , OR YAT SUN , WANG GUOQIANG , XU GUOYOU
发明人： QIU YAO-LING , PENG XIAOWEN , KIM IN JONG , CAO HUI , TANG DATONG , OR YAT SUN , WANG GUOQIANG , XU GUOYOU
IPC分类号： C07D209/54
CPC分类号： C07D209/54
摘要： The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (la), (lb) and (Ic):
摘要翻译：本发明一般涉及一种制备5-氮杂螺[2.4]庚烷-6-羧酸及其衍生物的改进方法，其在合成生物活性分子中是有用的中间体，特别是在合成肝素C病毒NS5A抑制剂。特别地，本发明涉及制备式（Ia），（Ib）和（Ic）化合物的方法和中间体：

5. 发明申请

WO2012021704A1 HEPATITIS C VIRUS INHIBITORS 审中-公开
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：WO2012021704A1
公开(公告)日：2012-02-16
申请号：PCT/US2011/047417
申请日：2011-08-11
申请人： ENANTA PHARMACEUTICALS, INC. , QIU, Yao-ling , PENG, Xiaowen , WANG, Ce , OR, Yat, Sun
发明人： QIU, Yao-ling , PENG, Xiaowen , WANG, Ce , OR, Yat, Sun
IPC分类号： A01N43/50 , A61K31/415
CPC分类号： C07D417/14 , A61K31/137 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K45/06 , C07D403/14 , C07D413/14 , C07D498/08 , A61K2300/00
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:(I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：（I）抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

6. 发明申请

WO2010148006A1 HEPATITIS C VIRUS INHIBITORS 审中-公开
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：WO2010148006A1
公开(公告)日：2010-12-23
申请号：PCT/US2010/038699
申请日：2010-06-15
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , PENG, Xiaowen , YING, Lu , TANG, Datong , WANG, Ce , QIU, Yao-ling
发明人： OR, Yat, Sun , PENG, Xiaowen , YING, Lu , TANG, Datong , WANG, Ce , QIU, Yao-ling
IPC分类号： A61K31/55
CPC分类号： C07D487/04 , C07D471/04 , C07D498/04 , C07D513/04
摘要： The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

7. 发明申请

WO2009039177A1 6, 11-BICYCLOIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES 审中-公开
标题翻译： 6,11-双羟基苯甲酸酯：桥联二异氰酸酯衍生物
公开(公告)号：WO2009039177A1
公开(公告)日：2009-03-26
申请号：PCT/US2008/076681
申请日：2008-09-17
申请人： ENANTA PHARMACEUTICALS, INC. , KIM, In, Jong , LIU, Tongzhu , QIU, Yao-Ling , PHAN, Ly, Tam , OR, Yat, Sun
发明人： KIM, In, Jong , LIU, Tongzhu , QIU, Yao-Ling , PHAN, Ly, Tam , OR, Yat, Sun
IPC分类号： A61K31/7052 , C07H17/08
CPC分类号： C07H17/08 , C07D213/69 , C07D213/80 , C07D309/40 , C07D498/12
摘要： The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: formula (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：具有抗菌性质的式（I）。本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

8. 发明申请

WO2011091417A1 HEPATITIS C VIRUS INHIBITORS 审中-公开
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：WO2011091417A1
公开(公告)日：2011-07-28
申请号：PCT/US2011/022401
申请日：2011-01-25
申请人： ENANTA PHARMACEUTICALS, INC. , QIU, Yao-Ling , WANG, Ce , PENG, Xiaowen , YING, Lu , CAO, Hui , OR, Yat, Sun
发明人： QIU, Yao-Ling , WANG, Ce , PENG, Xiaowen , YING, Lu , CAO, Hui , OR, Yat, Sun
IPC分类号： A01N43/00
CPC分类号： C07D498/18 , C07D519/00 , C07F9/6561
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W (I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）的化合物及其药学上可接受的盐，酯或前药：抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的Q-G-A-L-B-W（I）因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

9. 发明申请

WO2010030858A1 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES 审中-公开
标题翻译： 4'-ALLENE取代的核苷衍生物
公开(公告)号：WO2010030858A1
公开(公告)日：2010-03-18
申请号：PCT/US2009/056631
申请日：2009-09-11
申请人： ENANTA PHARMACEUTICALS, INC. , QIU, Yao-ling , WANG, Ce , PENG, Xiaowen , YING, Lu , OR, Yat, Sun
发明人： QIU, Yao-ling , WANG, Ce , PENG, Xiaowen , YING, Lu , OR, Yat, Sun
IPC分类号： C07D501/00
CPC分类号： C07H19/06 , C07H23/00
摘要： The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: Formula (I) which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
摘要翻译：本发明公开了式（I）化合物或其β-L对映体或其药学上可接受的盐，酯，立体异构体，互变异构体，溶剂合物，前药或其组合：抑制，预防或治疗异常细胞的式（I）增殖和/或病毒感染，特别是HIV，HCV或HBV。因此，本发明的化合物干扰病毒的复制周期，也可用作抗病毒剂，或干扰宿主细胞生物化学过程，也可用作抗增殖剂。本发明还涉及药物组合物，其包含用于给患有病毒感染和/或细胞增殖的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上文所述的新的抗病毒/抗增殖化合物，包含这些化合物的药物组合物，以及用于治疗或预防需要用所述化合物治疗的受试者的病毒感染的方法。

10. 发明申请

WO2008019240A2 3, 6-BRIDGED TYLOSIN DERIVATIVES 审中-公开
标题翻译： 3,6-桥联的TYLOSIN衍生物
公开(公告)号：WO2008019240A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/074687
申请日：2007-07-30
申请人： ENANTA PHARMACEUTICALS, INC. , QIU, Yao-Ling , LIU, Tongzhu , OR, Yat, Sun , PHAN, Ly, Tam
发明人： QIU, Yao-Ling , LIU, Tongzhu , OR, Yat, Sun , PHAN, Ly, Tam
IPC分类号： A61K31/7048 , A61P25/00 , A61P31/04 , C07H17/08
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof, which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了具有抗菌特性的式（I）化合物或其药学上可接受的盐，酯或前药。本发明还涉及包含前述化合物的药物组合物，用于向需要抗生素治疗的受试者施用。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式